अभी पंजीकरण करें

लॉग इन करें

पासवर्ड खो गया

आपका पासवर्ड खो गया है? कृपया अपना पूरा ईमेल दर्ज करें. आपको एक लिंक प्राप्त होगा और आप ईमेल के माध्यम से एक नया पासवर्ड बनाएंगे.

पोस्ट जोड़ें

पोस्ट जोड़ने के लिए आपको लॉगिन करना होगा .

प्रश्न जोड़ें

प्रश्न पूछने के लिए आपको लॉगिन करना होगा.

लॉग इन करें

अभी पंजीकरण करें

स्कॉलरसार्क.कॉम में आपका स्वागत है! आपका पंजीकरण आपको इस प्लेटफॉर्म की अधिक सुविधाओं का उपयोग करने की अनुमति देगा. आप सवाल पूछ सकते हैं, योगदान दें या उत्तर दें, अन्य उपयोगकर्ताओं के प्रोफ़ाइल देखें और बहुत कुछ. अभी पंजीकरण करें!

यूएस एफडीए ने अग्नाशय के कैंसर के लिए एस्ट्राजेनेका दवा का समर्थन किया

कैम्ब्रिज फार्मास्युटिकल दिग्गज एस्ट्राजेनेका और मर्क & Co ने Lynparza . के लिए अनाथ ड्रग पदनाम का US FDA पुरस्कार जीता है (ले रहा) अग्नाशय के कैंसर के उपचार के लिए. The core IP behind the technology arose from discoveries made by Professor Steve Jackson’s Cancer Research UK-funded team in Cambridge. Lynparza is bolt-on the next blockbuster drug with Cambridge roots. This is the fourth Orphan Drug Designation in the US for AstraZeneca and Merck’s Lynparza.

Photo credit: AstraZeneca

Pancreatic cancer is a rare, life-threatening disease that accounts for some three per cent of all cancers in the US.

Due to the late onset of symptoms patients are often diagnosed after the cancer has progressed to locally advanced or metastatic stages of the disease. Five-year survival rates remain low – 8.5 per cent in the US, उदाहरण के लिए.

Sean Bohen, AstraZeneca’s executive VP for Global Medicines Development and chief medical officer said: “Pancreatic cancer is an area of significant unmet medical need. This is especially true for patients with metastatic disease where the benefits of current treatment options are very limited.”

Roy Baynes, chief medical officer, at MSD Research Laboratories, said the FDA grant of Orphan Drug Designation was a positive step for patients with pancreatic cancer and continued to reinforce the importance of the collaboration in bringing Lynparza to more patients in need.

ODD status was granted for the treatment of ovarian cancer in October 2013. Earlier this year an amended ODD status was granted to include both fallopian tube and primary peritoneal cancers.

The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

The use of Lynparza in pancreatic cancer is being assessed in the ongoing Phase III POLO trial, which is testing Lynparza as maintenance monotherapy vs placebo in patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed following 1st-line platinum-based chemotherapy. Results from the POLO trial are expected in the first half of 2019.

Lynparza was the first in class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.

में प्राप्त संख्या जोड़ें, in vitro studies have shown that Lynparza-induced cytotoxicity may involve inhibition of PARP-enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.

Lynparza, which has the broadest clinical development programme of any PARP inhibitor, is being investigated in a range of DDR-deficient tumour types, and is the foundation of AstraZeneca’s industry-leading portfolio of compounds targeting DDR mechanisms in cancer cells.



के बारे में मैरी

उत्तर छोड़ दें